• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

香港的肾淀粉样变性的临床特征和转归。

Clinical features and outcomes of renal amyloidosis in Hong Kong.

机构信息

Department of Medicine and Geriatrics, Caritas Medical Centre, Kowloon, Hong Kong.

Department of Medicine and Geriatrics, Yan Chai Hospital, New Territory, Hong Kong.

出版信息

Nephrology (Carlton). 2022 Nov;27(11):869-876. doi: 10.1111/nep.14089. Epub 2022 Aug 25.

DOI:10.1111/nep.14089
PMID:36054582
Abstract

AIM

Early symptoms of primary (AL) amyloidosis are non-specific. Any delay in diagnosis and treatment results in poor outcome despite increasing treatment options. We aimed to determine baseline risk factors that identify patients with poor kidney outcomes and overall survivals.

METHODS

We recruited all patients aged 18 years or above with biopsy-proven renal amyloidosis between years 2000 and 2019 in three Hong Kong regional hospitals. Patients' clinical and pathological parameters, treatment response, kidney outcomes and overall survivals were recorded and analysed.

RESULTS

Thirty-six cases of renal amyloidosis were recruited. Four cases were diagnosed to have multiple myeloma. Edema was the most common presenting symptom. The mean estimated glomerular filtration rate (eGFR) was 98.8 ml/min/1.73 m at presentation. Autologous stem cell transplant conferred the best renal outcomes as well as patients' survival. Twenty-two patients had 50% decrease in eGFR, 12 patients developed end-stage kidney disease (ESKD) and 22 patients died. Hypertension, diabetes mellitus, proteinuria and low eGFR were identified as independent baseline risk factors for ESKD. Proteinuria, hyperlipidemia, and cardiac involvement were independent baseline risk factors for death.

CONCLUSION

Amyloidosis, a rare disease with poor prognosis without treatment. Hypertension, diabetes mellitus, heavy proteinuria and low eGFR at diagnosis were associated with poor kidney outcome.

摘要

目的

原发性(AL)淀粉样变性的早期症状是非特异性的。尽管治疗选择越来越多,但任何诊断和治疗的延迟都会导致预后不良。我们旨在确定基线风险因素,以识别具有不良肾脏结局和总体生存率的患者。

方法

我们招募了 2000 年至 2019 年间在香港三家地区医院通过活检证实的年龄在 18 岁或以上的所有肾淀粉样变性患者。记录并分析了患者的临床和病理参数、治疗反应、肾脏结局和总体生存率。

结果

共招募了 36 例肾淀粉样变性患者。4 例被诊断为多发性骨髓瘤。水肿是最常见的首发症状。就诊时平均估算肾小球滤过率(eGFR)为 98.8ml/min/1.73m。自体干细胞移植对肾脏结局和患者生存均有最佳效果。22 例患者 eGFR 下降 50%,12 例患者发展为终末期肾病(ESKD),22 例患者死亡。高血压、糖尿病、蛋白尿和低 eGFR 是 ESKD 的独立基线危险因素。蛋白尿、高脂血症和心脏受累是死亡的独立基线危险因素。

结论

淀粉样变性是一种预后不良的罕见疾病,如果不治疗,预后更差。诊断时的高血压、糖尿病、大量蛋白尿和低 eGFR 与不良肾脏结局相关。

相似文献

1
Clinical features and outcomes of renal amyloidosis in Hong Kong.香港的肾淀粉样变性的临床特征和转归。
Nephrology (Carlton). 2022 Nov;27(11):869-876. doi: 10.1111/nep.14089. Epub 2022 Aug 25.
2
Light-chain amyloidosis with renal involvement: renal outcomes and validation of two renal staging systems in the Chinese population.伴有肾脏受累的轻链淀粉样变性:中国人群的肾脏结局和两种肾脏分期系统的验证。
Amyloid. 2019 Dec;26(4):186-191. doi: 10.1080/13506129.2019.1639149. Epub 2019 Jul 24.
3
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.AL型和AA型肾淀粉样变性的长期预后:日本单中心经验
Clin Exp Nephrol. 2017 Apr;21(2):212-227. doi: 10.1007/s10157-016-1271-y. Epub 2016 Apr 26.
4
Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.AL 淀粉样变性自体干细胞移植中急性肾损伤的预测因素和结果。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1281-1288. doi: 10.1093/ndt/gfab189.
5
Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.重度AL淀粉样变性且经活检证实有肾脏受累而不符合骨髓移植条件的患者的预后。
J Nephrol. 2021 Feb;34(1):231-240. doi: 10.1007/s40620-020-00748-7. Epub 2020 May 29.
6
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.淀粉样变性肾病患者的肾脏结局:预后因素、肾脏反应及治疗的影响。
Am J Hematol. 2017 Jul;92(7):632-639. doi: 10.1002/ajh.24738. Epub 2017 May 26.
7
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.白细胞趋化因子 2(ALECT2)淀粉样变的诊断、发病机制和转归。
Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.
8
Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.系统性淀粉样变性中的肾脏受累:一项关于生存和肾脏结局的意大利协作研究。
Nephrol Dial Transplant. 2008 Mar;23(3):941-51. doi: 10.1093/ndt/gfm684. Epub 2007 Oct 19.
9
Clinical and laboratory profile of renal amyloidosis: A single-center experience.肾淀粉样变性的临床和实验室特征:单中心经验
Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1065-1072. doi: 10.4103/1319-2442.243966.
10
Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: A large retrospective case series study from a single institute in China.肾意义单克隆丙种球蛋白血症的肾脏病理谱和临床转归:来自中国单一机构的一项大型回顾性病例系列研究。
Nephrology (Carlton). 2020 Mar;25(3):202-211. doi: 10.1111/nep.13633. Epub 2019 Aug 1.